Janux Therapeutics (JANX) Non-Current Deffered Revenue (2020 - 2026)

Janux Therapeutics (JANX) has 5 years of Non-Current Deffered Revenue data on file, last reported at $8.7 million in Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $8.7 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $8.7 million (changed N/A YoY), and the FY2022 annual result was $2.2 million, up 217.29% from the prior year.
• Non-Current Deffered Revenue improved to $8.7 million in Q1 2026 per JANX's latest filing, from $307000.0 in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $8.7 million in Q1 2026 and troughed at $307000.0 in Q2 2023.
• A 3-year average of $3.6 million and a median of $3.0 million in 2022 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue surged 217.29% in 2022, then plunged 94.2% in 2023.
• A 3-year view of Non-Current Deffered Revenue shows it stood at $2.2 million in 2022, then sank by 86.18% to $307000.0 in 2023, then soared by 2726.06% to $8.7 million in 2026.
• Business Quant data shows JANX's Non-Current Deffered Revenue at $8.7 million in Q1 2026, $307000.0 in Q2 2023, and $1.4 million in Q1 2023.